九游盛世娱乐官网下载安装,九游盛世娱乐官网下载 Industry Overview Biopharmaceutical CDMO/CMO Industry Overview Products & services Formulation API Innovative Drugs Intermediate CDMO CRO Products & services Innovation & development Hangzhou Research Institute Experts Research Cooperation Innovation & development Investors & media AnnouncementMedia center Investors & media About us Company Profile History Mission & Vision Core value Contact Us Company News Our Company Career Development Talent Concept Social Recruitment Campus Recruitment Career Development Investorsand the media Announcement Media center Company NewsIndustry News Company NewsHome > Investors & media > Company News Congratulations: Allsino Chemicals Co. Ltd was awarded the SK Pharmteco Preferred Partner Source: Sinopep Preparations     Time: [2022-11-17] On November 2nd, 2022, during the CPHI worldwide Frankfurt event in Germany, Allsino Chemicals Co. Ltd (Allsino) has been highly honored and grateful to be awarded the SK Pharmteco Partner ’s award from SK Pharmteco company. This prize is distributed only to a selective choice of suppliers worldwide, to recognize them as the best suppliers worldwide to SK Pharmteco. Nearly 100 suppliers worldwide have been evaluated according to strict criteria, 10 have been awarded, among which Allsino, who was the only Chinese company selected.   SK Pharmteco is a U.S.-based contract manufacturing organization (CMO) and the holding company of South Korea's SK Group (SK Biotech, AMPAC Fine Chemicals, AMPAC Analytical and Yposkesi). SK Pharmteco specializes in the commercial and clinical production of APIs, advanced intermediates, registered starting materials, key building blocks and viral vectors. They provide global operations throughout their cGMP manufacturing and development facilities across the United States, Korea, Ireland, and France.   Founded in 2004 and 100% subsidiary of the company Sinopep-Allsino Biopharmaceutical Co Ltd. (stock code: 688076), Allsino is a first-class Contract Development and Manufacturing Organization (CDMO), based in Hangzhou, China. It is an innovation-driven biopharmaceutical company, committed to the research and development, manufacturing and sales of pharmaceutical products for advanced intermediates and drugs substances (small molecules, peptides), having its main markets in the USA, Europe & other industrially developed countries.   Throughout independent R&D and global technical collaboration, the company successfully initiated & developed more than 300 projects, including anti-cancer drugs, anti-depressant drugs, anti-hepatitis drugs, registered intermediates, and other high-tech products. All projects, whether it reached industrial, obtained patents, or stayed at small scale, ever enrich the company with deep experience in the field of exclusive custom synthesis, and enable Allsino to constantly seek and achieve ever higher levels of requirements for their global customers’ complex needs. Thanks to Allsino’s unwavering commitment to high standards complying with Western pharmaceutical requirements, good quality management, and sustainable improvement, many big pharmaceutical companies have partnered with Allsino.     Next > Industry OverviewProducts & services CDMO/CMO Products & servicesFormulation API Innovative Drugs Intermediate CDMO CRO Innovation & development Hangzhou Research Institute Experts Research Cooperation Investors and mediaAnnouncementMedia center About usCompany Profile History Mission & Vision Core value Contact Us Company News Career DevelopmentTalent Concept Social Recruitment Campus Recruitment Mobile version Copyright(C)2020, Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. All Rights Reserved. Supported by ChemNet ChinaChemNet Toocle Copyright Notice 中文版 Contact Sales Department: +86-571-88671216 (FDF) +86-571-88672696 (API and intermediates) 九游盛世娱乐官网下载安装,九游盛世娱乐官网下载